Tafamidis 61mg capsules
NHS hospitals in England used £256,226,300 of indicative cost of Tafamidis 61mg capsules in the 12 months to July 2026, about 1.0% of all hospital medicines spend. That is up 53.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Tafamidis 61mg capsules: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Tafamidis 61mg capsules most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Free London Nhs Foundation Trust | £253,480,255 |
| Barts Health Nhs Trust | £801,375 |
| Oxford University Hospitals Nhs Ft | £363,290 |
| Liverpool Heart & Chest Hosp Found Trust | £352,605 |
| University Hospital Southampton Nhs Ft | £256,440 |
| St George's Univ Hosps Foundation Nhst | £245,755 |
| University Hpls North Midlands Nhs Trust | £235,070 |
| Guy's & St Thomas' Nhs Foundation Trust | £224,385 |
| Leeds Teaching Hpls Nhs Trust | £149,590 |
| Univ Hpl B/Ham Nhs Foundation Trust | £74,795 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.